These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38398096)

  • 1. Infrequent Presentations of Chronic
    Castaño-Díez S; Guijarro F; López-Guerra M; Pérez-Valencia AI; Gómez-Núñez M; Colomer D; Díaz-Beyá M; Esteve J; Rozman M
    Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398096
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Forghieri F; Nasillo V; Paolini A; Bettelli F; Pioli V; Giusti D; Gilioli A; Colasante C; Acquaviva G; Riva G; Barozzi P; Maffei R; Potenza L; Marasca R; Fozza C; Tagliafico E; Trenti T; Comoli P; Longo G; Luppi M
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
    Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
    Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
    Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
    Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic myelomonocytic leukemia associated with myeloid sarcomas and
    Matanes F; AbdelAzeem BMA; Shah G; Reddy V; Saad A; Papadantonakis N
    Ther Adv Hematol; 2019; 10():2040620719854596. PubMed ID: 31217941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation.
    Peng J; Zuo Z; Fu B; Oki Y; Tang G; Goswami M; Priyanka P; Muzzafar T; Medeiros LJ; Luthra R; Wang SA
    Eur J Haematol; 2016 Jan; 96(1):65-71. PubMed ID: 25809997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Nucleophosmin 1 (
    Kelemen K
    Life (Basel); 2022 Jan; 12(1):. PubMed ID: 35054502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic and genetic characterization of nonacute
    Patel SS; Ho C; Ptashkin RN; Sadigh S; Bagg A; Geyer JT; Xu ML; Prebet T; Mason EF; Seegmiller AC; Morgan EA; Steensma DP; Winer ES; Wong WJ; Hasserjian RP; Weinberg OK
    Blood Adv; 2019 May; 3(9):1540-1545. PubMed ID: 31085507
    [No Abstract]   [Full Text] [Related]  

  • 9. NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage.
    Gener-Ricos G; Bataller A; Rodriguez-Sevilla JJ; Chien KS; Quesada AE; Almanza-Huante E; Hammond D; Sasaki K; DiNardo C; Kadia T; Daver N; Borthakur G; Issa GC; Short NJ; Kanagal-Shamanna R; Kantarjian HM; Garcia-Manero G; Montalban-Bravo G
    Cancer; 2024 Oct; 130(20):3452-3462. PubMed ID: 38896064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How I diagnose and treat NPM1-mutated AML.
    Falini B; Brunetti L; Martelli MP
    Blood; 2021 Feb; 137(5):589-599. PubMed ID: 33171486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center].
    Qu SQ; Pan LJ; Qin TJ; Xu ZF; Li B; Wang HJ; Sun Q; Jia YJ; Li CW; Cai WY; Gao QY; Jiao M; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):373-379. PubMed ID: 37550186
    [No Abstract]   [Full Text] [Related]  

  • 12. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
    Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
    Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression in Myeloid Neoplasms: Beyond the Myeloblast.
    Faria C; Tzankov A
    Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome.
    Mason EF; Hasserjian RP; Aggarwal N; Seegmiller AC; Pozdnyakova O
    Blood Adv; 2019 Nov; 3(21):3322-3332. PubMed ID: 31698462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
    Patel JL; Schumacher JA; Frizzell K; Sorrells S; Shen W; Clayton A; Jattani R; Kelley TW
    Leuk Res; 2017 May; 56():7-12. PubMed ID: 28152414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes.
    Papadopoulou V; Schoumans J; Basset V; Solly F; Pasquier J; Blum S; Spertini O
    Hematology; 2023 Dec; 28(1):2180704. PubMed ID: 36815747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD123 Is Consistently Expressed on
    Perriello VM; Gionfriddo I; Rossi R; Milano F; Mezzasoma F; Marra A; Spinelli O; Rambaldi A; Annibali O; Avvisati G; Di Raimondo F; Ascani S; Falini B; Martelli MP; Brunetti L
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33525388
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
    Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
    Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1.
    Zhao D; Zarif M; Eladl E; Capo-Chichi JM; Smith AC; Atenafu EG; Tierens A; Minden MD; Schuh A; Chang H
    Leuk Res; 2022 Jul; 118():106869. PubMed ID: 35636054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.